title: The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
authors.forename: M
authors.initials: M
authors.lastname: Kremer
authors.forename: T
authors.initials: T
authors.lastname: Horn
authors.forename: T
authors.initials: T
authors.lastname: Dechow
authors.forename: A
authors.initials: A
authors.lastname: Tzankov
authors.forename: L
authors.initials: L
authors.lastname: Quintanilla-Martínez
authors.forename: F
authors.initials: F
authors.lastname: Fend
mesh_terms: D003937:Diagnosis, Differential; D005355:Fibrosis; D005819:Genetic Markers; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D009190:Myelodysplastic Syndromes / Q000235:genetics* / Q000473:pathology*; D009196:Myeloproliferative Disorders / Q000235:genetics / Q000473:pathology; D017354:Point Mutation; D055728:Primary Myelofibrosis / Q000235:genetics* / Q000473:pathology*
chemical_list: D005819:Genetic Markers; C507924:JAK2 protein, human; D053614:Janus Kinase 2